Figure 1. Generating neuritin-overexpressed transgenic mouse line and constructing transient global ischemia model of transgenic mice. (A) Neuritin mRNA level in tail tissue of wild-type (WT) and transgenic (Nrn1-Tg) mice. (B) Neuritin mRNA expression level in hippocampus (HP) of the screened Nrn1-Tg and WT groups. (C) Southern blotting analysis to evaluate the number of integration site in transgenic mice identified by qRT-PCR. Lane 1: pcDNA3.1-neuritin plasmid. Lane 2: genomic DNA of wild type mouse. Lanes 3-9: genomic DNA of transgenic mice with the transgene expression. (D) Neuritin mRNA level in hippocampus of Nrn1-Tg and WT mice on day 1, 3, 7, and 14 post-TGI. GAPDH was used as the internal control. Data expressed as mean ± SEM and compared by Student’s t-test (p<0.05 considered statistically significant). *p< 0.05, **p< 0.01 versus WT, n=3 mice per group with triplicate biological replicates.